ArticleScientific reports2026
Impact of preserved ratio impaired spirometry on postoperative outcomes of non-small cell lung cancer surgery.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Preserved ratio impaired spirometry (PRISm) is associated with increased morbidity and mortality. However, the impact of PRISm on the postoperative outcomes of non-small cell lung cancer (NSCLC) surgery remains poorly understood. We retrospectively analyzed data of 834 patients with NSCLC from the prospective CATCH-LUNG cohort who underwent curative lung resection between March 2016 and December 2020. The patients were categorized into four groups: normal, PRISm, mild obstructive lung disease (OLD), and moderate OLD. The primary outcomes were postoperative pulmonary complications (PPCs) and cardiac complications (PCCs) that occurred within 30 days post-surgery. The incidences of PPCs and PCCs were significantly higher in the PRISm group (PPC: 11.5%; PCC: 16.4%) than in the normal lung function group (PPC: 3.3%; PCC: 4.6%). Patients with PRISm had adjusted RRs of 2.62 (95% CI: 1.10–6.23) for PPCs and 2.67 (95% CI: 1.42–4.99) for PCCs. The adjusted RRs for PPCs were 2.32 in mild OLD and 3.25 in moderate OLD, whereas those for PCCs were 1.94 in mild OLD and 2.32 in moderate OLD. Notably, among patients with PRISm, those with low FVC (<80% predicted) had markedly higher risks of PPCs (adjusted RR = 3.41; 95% CI: 1.22–9.54) and PCCs (adjusted RR = 3.31; 95% CI: 1.74–6.31) compared to those with normal FVC. PRISm, like chronic obstructive pulmonary disease, substantially increases the risk of postoperative complications of NSCLC surgery and should be recognized as an important clinical category.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.